| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9271437 | Journal of Infection and Chemotherapy | 2005 | 5 Pages |
Abstract
We report here a case of culture-proven Legionnaires' disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. The patient was a 51-year-old man hospitalized after a diagnosis of community-acquired pneumonia. Legionella pneumophila SG1 was isolated from the patient's bronchoalveolar lavage (BAL) fluid, and the soluble antigen of the bacterium was detected in the fluid as well. Subsequently, intravenous PZFX was administered for a week and proved markedly effective. An in vitro study confirmed that PZFX had excellent extracellular and intracellular activity against the isolate from the patient. This case suggests that PZFX is an option for treating Legionnaires' disease.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Futoshi Higa, Takashi Shinzato, Masato Toyama, Shusaku Haranaga, Makoto Furugen, Masao Tateyama, Kazuyoshi Kawakami, Atsushi Saito,